CCL22 and neoplasm: Concurrently, an increase in immune counter-regulatory and tumor-associated markers was observed at relapse, including genes involved in immune suppression, CTLA-4, CCR4 (ref. 38) and CCL22 (ref. 39) (Extended Data Fig. 8d; upper row, FFPE biopsies, and lower row, FF biopsies).